Sysmex Partec GmbH products

Highly sensitive down to 0.06 % MAF, Able to detect 6 MM with 95 % confidence across all mutations (absolute quantification), High flexibility of between 2-16 samples/run, Fast TAT (2 days), Convenient software. Plasma-SeqSensei (PSS) BC RUO Kit allows for the highly sensitive and specific detection of mutations in circulating tumour DNA (ctDNA) from the plasma of patients with breast cancer. The kit is based on the next-generation sequencing technology and covers key gene mutations such as AKT1, ERBB2, ESR1, KRAS, PIK3CA and TP53 to detect established and emerging predictive markers, resistance mutations, and frequently occurring genetic alterations in breast cancer. These genes significantly contribute to the development of breast cancer and are important biomarkers utilised for the choice of therapy, prognosis as well as monitoring of recurrence and therapy response.

Precise lymph node analysis providing accurate staging, Reliable diagnostic information for therapy decision, High flexibility in multi-cancer application (CE-marked for breast, colon and gastric cancer). Axillary management and the relevance of sentinel lymph node biopsy (SLNB) have undergone major changes in the last years. Clinical trials, which have investigated less invasive treatment approaches as a replacement of axillary surgery, indicate that axillary dissection can be omitted in patients with limited metastatic involvement. Consequently, treatment decisions and nodal staging more often have to be based solely on the diagnostic information derived from the sentinel lymph node (SLN).